T. Rowe Price Investment Management
CRNX icon

T. Rowe Price Investment Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

T. Rowe Price Investment Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$75.2M Buy
2,010,288
+69,666
+4% +$2.59M 0.05% 324
2026
Q1 		$70.5M Buy
1,940,622
+1,881,501
+3,182% +$84M 0.05% 299
2025
Q4 		$2.75M Sell
59,121
-1,463
-2% -$65.1K ﹤0.01% 607
2025
Q3 		$2.52M Sell
60,584
-655,588
-92% -$21M ﹤0.01% 602
2025
Q2 		$20.6M Buy
716,172
+26,907
+4% +$831K 0.01% 496
2025
Q1 		$23.1M Sell
689,265
-313,617
-31% -$11.7M 0.02% 499
2024
Q4 		$51.3M Sell
1,002,882
-65,650
-6% -$3.67M 0.03% 404
2024
Q3 		$54.6M Sell
1,068,532
-278,678
-21% -$14.4M 0.03% 394
2024
Q2 		$60.3M Sell
1,347,210
-1,307,519
-49% -$60.4M 0.04% 367
2024
Q1 		$124M Buy
2,654,729
+237,236
+10% +$9.28M 0.08% 256
2023
Q4 		$86M Buy
2,417,493
+776,801
+47% +$23.8M 0.06% 301
2023
Q3 		$48.8M Buy
1,640,692
+676,687
+70% +$13.9M 0.03% 367
2023
Q2 		$17.4M Buy
964,005
+34,636
+4% +$691K 0.01% 490
2023
Q1 		$14.9M Buy
+929,369
New +$17.2M 0.01% 492

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management's CRNX Position: Q2 2026 in Review

T. Rowe Price Investment Management increased its Crinetics Pharmaceuticals (CRNX) stake by 3.6% in Q2 2026, buying an estimated $2.59M and bringing the position to 2,010,288 shares worth $75.2M. The position accounts for 0.05% of the portfolio, ranked #324.

T. Rowe Price Investment Management first reported a position in CRNX in Q1 2023 and has held it in 14 quarters since. The position peaked at $124M in Q1 2024. 266 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • T. Rowe Price Investment Management held 2,010,288 shares of Crinetics Pharmaceuticals worth $75.2M as of Q2 2026.
  • T. Rowe Price Investment Management bought 69,666 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $2.59M.
  • Crinetics Pharmaceuticals made up 0.05% of T. Rowe Price Investment Management's portfolio in Q2 2026, its #324 holding.
  • T. Rowe Price Investment Management first reported a position in Crinetics Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
  • T. Rowe Price Investment Management's Crinetics Pharmaceuticals position peaked at $124M in Q1 2024.
  • 266 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.